Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Huyuan Yang

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2018
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myelomaMeletios A Dimopoulos, Sebastian Grosicki, Wiesław W Jędrzejczak, et al.
The Journal of Clinical Psychiatry|February 5, 2009
Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical featuresMadhukar H Trivedi, Michael E Thase, Maurizio Fava, et al.
British Journal of Haematology|May 20, 2016
A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysisNeeraj Gupta, Michael J Hanley, R Donald Harvey, et al.
Primary Care Companion to the Journal of Clinical Psychiatry|March 17, 2009
Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studiesMichael E Thase, Madhukar H Trivedi, J Craig Nelson, et al.
Inflammatory Bowel Diseases|October 9, 2018
Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1Walter Reinisch, Brian Bressler, Rebecca Curtis, et al.
Blood|May 28, 2017
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosisVaishali Sanchorawala, Giovanni Palladini, Vishal Kukreti, et al.
Journal of Crohn'S & Colitis|March 24, 2017
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's DiseaseMaria Rosario, Jonathan L French, Nathanael L Dirks, et al.
Journal of Hematology & Oncology|September 5, 2015
Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 studyNeeraj Gupta, Yeow Tee Goh, Chang-Ki Min, et al.
Journal of Crohn'S & Colitis|February 1, 2018
Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's DiseaseMaria Rosario, Jonathan L French, Nathanael L Dirks, et al.
Investigational New Drugs|May 21, 2017
A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase CKhaldoun Almhanna, David Wright, Teresa Macarulla Mercade, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2018
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myelomaMeletios A Dimopoulos, Sebastian Grosicki, Wiesław W Jędrzejczak, et al.
The Journal of Clinical Psychiatry|February 5, 2009
Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical featuresMadhukar H Trivedi, Michael E Thase, Maurizio Fava, et al.
British Journal of Haematology|May 20, 2016
A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysisNeeraj Gupta, Michael J Hanley, R Donald Harvey, et al.
Primary Care Companion to the Journal of Clinical Psychiatry|March 17, 2009
Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studiesMichael E Thase, Madhukar H Trivedi, J Craig Nelson, et al.
Inflammatory Bowel Diseases|October 9, 2018
Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1Walter Reinisch, Brian Bressler, Rebecca Curtis, et al.
Blood|May 28, 2017
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosisVaishali Sanchorawala, Giovanni Palladini, Vishal Kukreti, et al.
Journal of Crohn'S & Colitis|March 24, 2017
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's DiseaseMaria Rosario, Jonathan L French, Nathanael L Dirks, et al.
Journal of Hematology & Oncology|September 5, 2015
Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 studyNeeraj Gupta, Yeow Tee Goh, Chang-Ki Min, et al.
Journal of Crohn'S & Colitis|February 1, 2018
Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's DiseaseMaria Rosario, Jonathan L French, Nathanael L Dirks, et al.
Investigational New Drugs|May 21, 2017
A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase CKhaldoun Almhanna, David Wright, Teresa Macarulla Mercade, et al.
Pageof 2